Press releases

19 Dec 2022

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

13 Dec 2022

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

12 Dec 2022

Changes in UCB’s Board of Directors

9 Dec 2022

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

7 Dec 2022

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

1 Dec 2022

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Press releases

Press releases

Search Press releases

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

Changes in UCB’s Board of Directors

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

Changes in UCB’s Board of Directors

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Choose a Country